Evidence map›Paper›PMID 37821578›Full record

ArticleProstate cancer and prostatic diseases2024

Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men.

Matthew Epstein, Kaynaat Syed, John Danella, Serge Ginzburg, Laurence Belkoff, Jeffrey Tomaszewski, Edouard Trabulsi, Eric A Singer, Bruce L Jacobs, Jay D Raman and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

Matthew EpsteinDepartment of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.ORCID 0000-0001-6603-1959
Kaynaat SyedHealth Care Improvement Foundation, Philadelphia, PA, USA.
John DanellaGeisinger Health System, Danville, PA, USA.
Serge GinzburgEinstein Healthcare Network, Philadelphia, PA, USA.ORCID 0000-0002-7971-2056
Laurence BelkoffMidLantic Urology/Main Line Health, Bala Cynwyd, PA, USA.
Jeffrey TomaszewskiCooper University Health Care, Camden, NJ, USA.
Edouard TrabulsiThomas Jefferson University, Philadelphia, PA, USA.ORCID 0000-0002-1058-6493
Eric A SingerRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Bruce L JacobsUniversity of Pittsburgh, Pittsburgh, PA, USA.
Jay D RamanDepartment of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Thomas J GuzzoUniversity of Pennsylvania, Philadelphia, PA, USA.
Robert UzzoFox Chase Cancer Center, Philadelphia, PA, USA.
Adam C ReeseDepartment of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Adam.Reese@tuhs.temple.edu.ORCID 0000-0001-9587-9852
Cooper University Health Care · USEinstein Healthcare Network · USFox Chase Cancer Center · USGeisinger Health System · USMain Line Health · USPenn State Milton S. Hershey Medical Center · USRutgers, The State University of New Jersey · USTemple University · USTemple University Hospital · USThomas Jefferson University · USUniversity of Pennsylvania · USUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aims to determine if there is a difference in prostate cancer nomogram-adjusted risk of biochemical recurrence (BCR) and/or adverse pathology (AP) between African American (AAM) and Caucasian men (CM) undergoing radical prostatectomy (RP).

methodsA retrospective review was performed of men undergoing RP in the Pennsylvania Urologic Regional Collaborative between 2015 and 2021. Cox proportional hazard regression models were used to compare the rate of BCR after RP, and logistic regression models were used to compare rates of AP after RP between CM and AAM, adjusting for the CAPRA, CAPRA-S, and MSKCC pre- and post-operative nomogram scores.

resultsRates of BCR and AP after RP were analyzed from 3190 and 5029 men meeting inclusion criteria, respectively. The 2-year BCR-free survival was lower in AAM (72.5%) compared to CM (79.0%), with a hazard ratio (HR) of 1.38 (95% CI 1.16-1.63, p < 0.001). The rate of BCR was significantly greater in AAM compared to CM after adjustment for MSKCC pre-op (HR 1.29; 95% CI 1.08-1.53; p = 0.004), and post-op nomograms (HR 1.26; 95% CI 1.05-1.49; p < 0.001). There was a trend toward higher BCR rates among AAM after adjustment for CAPRA (HR 1.13; 95% CI 0.95-1.35; p = 0.17) and CAPRA-S nomograms (HR 1.11; 95% 0.93-1.32; p = 0.25), which did not reach statistical significance. The rate of AP was significantly greater in AAM compared to CM after adjusting for CAPRA (OR 1.28; 95% CI 1.10-1.50; p = 0.001) and MSKCC nomograms (OR 1.23; 95% CI 1.06-1.43; p = 0.007).

conclusionThis analysis of a large multicenter cohort provides further evidence that AAM may have higher rates of BCR and AP after RP than is predicted by CAPRA and MSKCC nomograms. Accordingly, AAM may benefit with closer post-operative surveillance and may be more likely to require salvage therapies.

Indexed as

Black or African AmericanNeoplasm Recurrence, LocalNomogramsProstatectomyProstate-Specific AntigenProstatic NeoplasmsAgedFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingPrognosisRetrospective StudiesRisk AssessmentRisk FactorsProstate-Specific Antigen

Identifiers

PMID37821578
OpenAlexW4387526195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.